Compare Summit Therapeutics Inc (SMMT) vs Symbotic Inc (SYM) Price & Performance

Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.

The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.

SYM trades at $42.73, down 1.34% today, with bearish technical signals dominating. The stock shows mixed fundamentals with strong revenue growth projected ($2.6B in 2026) but negative 2025 net income of -$16.94M. Recent earnings show two misses against expectations, though Q4 2025 beat estimates. Analyst consensus remains positive with 61% buy ratings and a $60.33 price target, representing 41% upside potential from current levels.

The outlook balances growth potential against execution risks. SYM's $22.5B backlog and expanding AI/robotics market position offer substantial upside, but customer concentration (85% Walmart revenue) and recent earnings misses create near-term uncertainty. Technical indicators suggest caution with bearish moving average signals, though oversold conditions may present entry opportunities for long-term investors.